Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2881-2890 Newer>

BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool May 8, 2006 Stephen D. Simpson	A Firm Backbone at Kyphon Medtronic begins a lawsuit, but Kyphon should continue to grow. However, these shares are on the expensive side, even for a fast-growing med-tech company.
The Motley Fool May 8, 2006 Stephen D. Simpson	Cytyc Looking Toward New Tech It's worth paying attention to this women's health company's transition to new growth drivers. Investors, take note.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
BusinessWeek May 15, 2006 Gene G. Marcial	Will Praecis Announce A Lucrative Deal? Praecis Pharmaceuticals, a small biotech company with an approved product for treating prostate cancer, may announce sometime this year the big deal it has been waiting for, according to analysts.
Chemistry World May 4, 2006 Katharine Sanderson	Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Pharmaceutical Executive May 1, 2006 Ron Feemster	Teamsters v. Pfizer A New Jersey Teamsters local says Pfizer tricked them into paying for off-label Lipitor prescriptions. Do you have any questions about that? We do.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Pharm Exec Q&A: Japanese Wedding Here, Daiichi Sankyo Pharma's John Alexander talks about the goals of its recent merger, the progress thus far, and shares insight into the development plans for its anti-platelet agent prasugrel.
<Older 2881-2890 Newer> Return to current articles.